Choice of Intravenous Iron Formulation
For most patients requiring IV iron infusion, use iron sucrose or sodium ferric gluconate rather than iron dextran, as they have superior safety profiles with no requirement for mandatory test dosing and significantly lower rates of serious adverse reactions.
Safety Profile Comparison
The evidence consistently demonstrates important safety differences between formulations:
Iron dextran (particularly high-molecular-weight formulations like Dexferrum) carries the highest risk of serious adverse events, including anaphylactic reactions at rates of 0.65-0.7% 1. Most adverse events historically associated with IV iron occurred with high-molecular-weight iron dextran 2.
Low-molecular-weight iron dextran (INFed) is safer than high-molecular-weight formulations but still requires mandatory test dosing (25 mg slow IV push, wait 1 hour) and carries a black box warning for anaphylaxis 2, 3. Life-threatening adverse events occur at approximately 3.3 per million doses 4.
Iron sucrose and sodium ferric gluconate have the most favorable safety profiles, with life-threatening adverse events occurring at only 0.6 and 0.9 per million doses respectively 4. Test doses are not required but may be considered at physician discretion for patients with prior sensitivities or multiple drug allergies 2.
Practical Administration Guidelines
Iron Sucrose
- Dosing: 200 mg IV over 60 minutes (or 2-5 minutes for rapid administration) 2
- Frequency: Every 2-3 weeks
- Maximum single dose: Do not exceed 300 mg 2
- Total dose: Up to 1000 mg cumulative
- No test dose required
Sodium Ferric Gluconate
- Dosing: 125 mg IV over 60 minutes 2
- Frequency: Once weekly for 8 doses
- Maximum single dose: Do not exceed 125 mg based on published trials 2
- Total dose: 1000 mg maximum
- No test dose required
Low-Molecular-Weight Iron Dextran (if used)
- Test dose mandatory: 25 mg slow IV push, observe 1 hour 2
- Dosing: 100 mg IV over 5 minutes 2
- Frequency: Weekly for 10 doses
- Alternative: Can give 500-1000 mg total dose infusion over several hours in non-hemodialysis patients 1
- Maximum: 1000 mg total
Clinical Context Considerations
For hemodialysis patients: All three formulations are effective, but iron sucrose and ferric gluconate avoid the test dose requirement and have lower adverse event rates 1, 5. A recent comparative study showed similar mortality outcomes but slightly fewer infectious complications with iron sucrose versus ferric gluconate (HR 0.92) 5.
For cancer patients receiving ESAs: All three formulations are acceptable, but if iron dextran is chosen, use only low-molecular-weight formulation (INFed) 2.
For general iron deficiency: Iron sucrose and ferric gluconate are preferred due to superior safety profiles 6, 4, 7, 8, 9.
Critical Safety Warnings
- Never use high-molecular-weight iron dextran (Dexferrum) - it is associated with unacceptably high adverse event rates up to 28% 3
- Do not administer IV iron to patients with active infection 2
- Dose-related arthralgias/myalgias occur with iron dextran at doses >100 mg, affecting up to 59% with total dose infusions 1
- Monitor patients during infusion for hypotension, hypertension, nausea, vomiting, dyspnea, and allergic reactions 2
Cost-Effectiveness Note
While iron dextran allows single large-dose administration (potentially more convenient), the cost to prevent one life-threatening adverse event by using iron sucrose instead of low-molecular-weight iron dextran is estimated at $5-7.8 million 4. However, the superior safety profile and elimination of mandatory test dosing make non-dextran formulations the preferred choice for routine clinical practice.